PharmaShots | Incisive News in 3 Shots

Subscribe Now

All Posts by Date

Novartis Reports P-III (MONALEESA-2/3/7) Study Results of Kisqali (ribociclib) for HR+/HER2- Advanced Breast Cancer

Novartis Reports P-III (MONALEESA-2/3/7) Study Results of Kisqali (ribociclib) for HR+/HER2- Advanced Breast Cancer

September 9, 2022

PharmaShots Weekly Snapshots (September 05 - 09, 2022)

PharmaShots Weekly Snapshots (September 05 - 09, 2022)

September 9, 2022

Pfizer Reports the US FDA and EMA's Acceptance of NDA & MAA for Ritlecitinib to Treat Alopecia Areata in Patients Aged ≥12 Years

Pfizer Reports the US FDA and EMA's Acceptance of NDA & MAA for Ritlecitinib to Treat Alopecia Areata in Patients Aged ≥12 Years

September 9, 2022

Abbott Launches Amplatzer Talisman PFO Occlusion System for the Treatment of Patent Foramen Ovale in the EU

Abbott Launches Amplatzer Talisman PFO Occlusion System for the Treatment of Patent Foramen Ovale in the EU

September 9, 2022

Regeneron Reports (PHOTON) and (PULSAR) Study Results of Aflibercept for Diabetic Macular Edema and Wet Age-Related Macular Degeneration

Regeneron Reports (PHOTON) and (PULSAR) Study Results of Aflibercept for Diabetic Macular Edema and Wet Age-Related Macular Degene...

September 9, 2022

Eli Lilly Presents P-III (ADvocate 1 & 2) Trial Results of Lebrikizumab for the Treatment of Atopic Dermatitis at EADV 2022

Eli Lilly Presents P-III (ADvocate 1 & 2) Trial Results of Lebrikizumab for the Treatment of Atopic Dermatitis at EADV 2022

September 9, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us